Vor Biopharma to Highlight Telitacicept at JPM Conference

Vor Biopharma ( (VOR) ) has provided an update.

Vor Biopharma announced that it will present and host one-on-one investor meetings at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on January 13, 2026, where it is highlighting telitacicept as a leading dual BAFF/APRIL inhibitor for B cell–mediated autoimmune diseases. The company emphasized that telitacicept already has an established commercial footprint and broad clinical data package in China through partner RemeGen across several autoimmune conditions, a favorable and predictable safety profile observed in about 1,800 clinical trial participants and tens of thousands of treated patients, and robust efficacy signals in generalized myasthenia gravis, while outlining a global development plan that includes a Phase 3 trial in generalized myasthenia gravis with topline data expected in the first half of 2027 and a Phase 3 trial in Sjögren’s disease planned to start in the first half of 2026, supported by approximately $450 million in cash and investments as of December 2025, which the company says provides runway into mid-2028 to fund these key milestones.

The most recent analyst rating on (VOR) stock is a Buy with a $50.00 price target. To see the full list of analyst forecasts on Vor Biopharma stock, see the VOR Stock Forecast page.

Spark’s Take on VOR Stock

According to Spark, TipRanks’ AI Analyst, VOR is a Neutral.

The score is held down primarily by weak financial performance (no revenue, large and worsening losses, and deeply negative equity). Corporate events provide a meaningful offset via Phase 3 progress and sizable financings that support continued clinical development, while technicals and valuation remain mixed and do not strongly improve the risk profile.

To see Spark’s full report on VOR stock, click here.

More about Vor Biopharma

Vor Biopharma is a biotechnology company focused on immune remodulation for B cell–driven autoimmune diseases through BAFF/APRIL inhibition. Its lead asset, telitacicept, is a selective BAFF/APRIL inhibitor designed to reduce pathogenic B cells and autoantibodies while preserving immune protection, and has been clinically validated and commercially approved in multiple autoimmune indications in China, including systemic lupus erythematosus, rheumatoid arthritis, and myasthenia gravis, with additional regulatory submissions for Sjögren’s disease and IgA nephropathy.

Average Trading Volume: 1,736,681

Technical Sentiment Signal: Sell

Current Market Cap: $280M

For detailed information about VOR stock, go to TipRanks’ Stock Analysis page.